ADCT · CIK 0001771910
What ADC Therapeutics SA told the SEC could break it.
ADC Therapeutics' disclosures are those of a single-product company fighting to fund itself. Essentially all its product revenue comes from one approved drug, ZYNLONTA for relapsed or refractory DLBCL, so any commercial setback, competition or label limit would be highly material. Its finances reflect that pressure: a 2025 restructuring closed its UK facility and cut roughly 30% of its global workforce, and it depends on a secured loan (with a $60 million qualified-cash covenant) and equity raises, including a $100 million June 2025 private placement, to keep operating. Compounding it, the company outsources all manufacturing of raw materials, components and finished product to third-party CMOs — many of them sole-source — for ADCs built on highly potent cytotoxins, so a single supply disruption could halt ZYNLONTA production.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Liquidity & debt
- restructuring & capital dependence (secured loan, equity raises)high
ADC Therapeutics undertook a 2025 restructuring — closing its UK facility and cutting ~30% of its global workforce — and depends on a secured loan (with a $60M qualified-cash covenant) and equity raises ($100M June 2025 private placement) to fund operations.
“On June 11, 2025, the Board of Directors approved the 2025 Restructuring, pursuant to which the Company closed down its UK facility, and has reduced its global workforce across functions by approximately 30 %.”
SEC filing →As of 2026
Sole-source dependency
- single-source CMOs / cytotoxin & component suppliershigh
ADC Therapeutics outsources all raw-material, component and finished-product manufacturing to third-party CMOs, many of which are sole-source suppliers, and its ADCs use highly potent cytotoxins/payloads — so a supply disruption or batch failure could halt ZYNLONTA production.
“We currently rely on third parties to manufacture all our raw materials, components and finished products, many of which are sole source suppliers, and this risk may be heightened by our reliance on CMOs to produce our products and product candidates.”
SEC filing →As of 2026
Other disclosures
- single approved product (ZYNLONTA)medium
ADC Therapeutics' product revenue derives essentially from a single approved product, ZYNLONTA (for relapsed/refractory DLBCL), so commercial setbacks, competition or label limits would be highly material.
“The Company generates revenue from sales of ZYNLONTA in the U.S. for the treatment of relapsed or refractory DLBCL after two or more lines of systemic therapy.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Overland ADCT BioPharma
“Overland ADCT BioPharma is responsible, at its sole cost, for the development, regulatory approval and commercialization of the Licensed Products in the Territory, and must use diligent efforts in order to obtain and maintain regulatory approval for and commercialize the products in each applicable jurisdiction.”
Cited →Swedish Orphan Biovitrum AB (Sobi)
“Sobi will conduct development and commercialization activities with respect to ZYNLONTA in the Covered Territory and bear the associated costs, other than the costs of global clinical studies that are intended to support regulatory approval in both the United States and the Covered Territory.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch